MRS methods used in the literature for detection of D-2 HG in patients with mutant IDH glioma

The investigation of metabolic pathways disturbed in isocitrate dehydrogenase (IDH) mutant tumors revealed that the hallmark metabolic alteration is the production of D-2-hydroxyglutarate (D-2HG). The biological impact of D-2HG strongly suggests that high levels of this metabolite may play a central role in propagating downstream the effects of mutant IDH, leading to malignant transformation of cells. Hence, D-2HG may be an ideal biomarker for both diagnosing and monitoring treatment response targeting IDH mutations. Magnetic resonance spectroscopy (MRS) is well suited to the task of noninvasive D-2HG detection, and there has been much interest in developing such methods. Here, we review recent efforts to translate methodology using MRS to reliably measure in vivo D-2HG into clinical research.

[1]  R. Deberardinis,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas , 2015 .

[2]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[3]  Eiji Kohmura,et al.  GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients , 2013, Journal of Neuro-Oncology.

[4]  D. Cahill,et al.  From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. , 2013, Neurosurgical focus.

[5]  Stéphane Lehéricy,et al.  Brain dynamic neurochemical changes in dystonic patients: A magnetic resonance spectroscopy study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[6]  Jerry J. Lou,et al.  Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. , 2013, Neuro-oncology.

[7]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[8]  S. Gross,et al.  Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. , 2012, ACS medicinal chemistry letters.

[9]  K. Sharp,et al.  Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production , 2012, Oncogene.

[10]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[11]  Erwin G. Van Meir,et al.  Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma , 2012, Journal of Molecular Medicine.

[12]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[13]  Aaron T. Hess,et al.  Real-time Motion and B0 correction for LASER MRSI using EPI volumetric navigators , 2012 .

[14]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[15]  Mitchel S. Berger,et al.  Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.

[16]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[17]  Hong Wu,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[18]  Peter Jezzard,et al.  Efficient γ‐aminobutyric acid editing at 3T without macromolecule contamination: MEGA‐SPECIAL , 2011, NMR in biomedicine.

[19]  A. V. D. van der Kouwe,et al.  Real‐time motion and B0 corrected single voxel spectroscopy using volumetric navigators , 2011, Magnetic resonance in medicine.

[20]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[21]  O. Chinot,et al.  IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients , 2011, Journal of Neuro-Oncology.

[22]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[23]  A. von Deimling,et al.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.

[24]  R. Edden,et al.  High resolution spectroscopic imaging of GABA at 3 Tesla , 2011, Magnetic resonance in medicine.

[25]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[26]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[27]  J. Golfinos,et al.  R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma , 2011, Acta Neuropathologica.

[28]  K. Yen,et al.  Cancer-associated IDH mutations: biomarker and therapeutic opportunities , 2010, Oncogene.

[29]  A Gregory Sorensen,et al.  Low‐power adiabatic sequences for in vivo localized two‐dimensional chemical shift correlated MR spectroscopy , 2010, Magnetic resonance in medicine.

[30]  Elaine Holmes,et al.  High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues , 2010, Nature Protocols.

[31]  Eva-Maria Ratai,et al.  Spectroscopic imaging with improved gradient modulated constant adiabaticity pulses on high-field clinical scanners. , 2010, Journal of magnetic resonance.

[32]  W. Vandertop,et al.  The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma , 2010, Acta Neuropathologica.

[33]  Franklyn A Howe,et al.  Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers , 2010, Molecular Cancer.

[34]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[35]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[36]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[37]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[38]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[39]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[40]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[41]  B. Ross,et al.  MR spectroscopy in diagnosis and neurological decision-making. , 2008, Seminars in neurology.

[42]  A. Tzika,et al.  Solid-state NMR adiabatic TOBSY sequences provide enhanced sensitivity for multidimensional high-resolution magic-angle-spinning 1H MR spectroscopy. , 2008, Journal of magnetic resonance.

[43]  L O Hall,et al.  Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging , 2006, NMR in biomedicine.

[44]  Peter Boesiger,et al.  Improved two‐dimensional J‐resolved spectroscopy , 2006, NMR in biomedicine.

[45]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[46]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[47]  A. Gryff-Keller,et al.  1H and 13C NMR study of 2‐hydroxyglutaric acid and its lactone , 2002 .

[48]  Jun Shen,et al.  In vivo GABA editing using a novel doubly selective multiple quantum filter , 2002, Magnetic resonance in medicine.

[49]  L DelaBarre,et al.  The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. , 2001, Journal of magnetic resonance.

[50]  R Lufkin,et al.  Localized two‐dimensional shift correlated MR spectroscopy of human brain , 2001, Magnetic resonance in medicine.

[51]  W P Dillon,et al.  Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. , 2001, AJNR. American journal of neuroradiology.

[52]  S. Arribas,et al.  Two-Dimensional Spectroscopy of NGC 2992 , 2001 .

[53]  W Dreher,et al.  Detection of homonuclear decoupled in vivo proton NMR spectra using constant time chemical shift encoding: CT-PRESS. , 1999, Magnetic resonance imaging.

[54]  M. Garwood,et al.  Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.

[55]  R. Gonzalez,et al.  Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A H Wilman,et al.  Yield enhancement of a double-quantum filter sequence designed for the edited detection of GABA. , 1995, Journal of magnetic resonance. Series B.

[57]  R. Mattson,et al.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Bottomley.  Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.

[59]  G. Bodenhausen,et al.  Principles of nuclear magnetic resonance in one and two dimensions , 1987 .